InvestorsHub Logo
Followers 13
Posts 865
Boards Moderated 0
Alias Born 02/17/2017

Re: TheBioTechG post# 16790

Tuesday, 08/22/2017 10:31:55 AM

Tuesday, August 22, 2017 10:31:55 AM

Post# of 232309
I think that it absolutely does, but it's a different patient set, a different treatment regimen, and I'm not a doctor. I don't think it's unreasonable to draw that conclusion though, particularly since the rebounders witnessed in the P2 trials occurred well before 25 weeks. Personally, I take it as a significant feather in the cap, and think that overall risk to mono and the company stepped down quite a bit yesterday.

That's just my opinion though. And failing the treatment regimen or not, combo is not mono, so it's definitely not 100% apples to apples.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News